Innovative Medicines Canada v. Canada (Attorney General), 2020 FC 725
| Jurisdiction | Federal Jurisdiction (Canada) |
| Court | Federal Court (Canada) |
| Citation | 2020 FC 725 |
| Date | 29 June 2020 |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
31 practice notes
-
Table of Cases
...Corporation v Canada (Health), 2008 FC 1409 .......................205, 208 Innovative Medicines Canada v Canada (Attorney General), 2020 FC 725 .....................................................................................296, 299 Innovative Medicines Canada v Canada (Attorney Gen......
-
Innovative Medicines Canada v. Canada (Attorney General), 2022 FCA 210
...decision to enact section 6 of S.O.R./2019-298—to change the list of comparator countries—was reasonable and, thus, the section was valid: 2020 FC 725 (per Manson J.). [7] For the reasons that follow, I agree with the Federal Court. Therefore, I would dismiss the appeal with costs. B. Analy......
-
TransAlta Generation Partnership v Alberta (Minister of Municipal Affairs),
...The Federal Court decision in Innovative Medicines Canada v Canada (Attorney General), 2020 FC 725 is similarly distinguishable. The court considered the meaning of the words “price” and “sale” in Regulations Amending the Patented Medicines Regulations (Additiona......
-
Alexion Pharmaceuticals Inc. v. Canada (Attorney General),
...patent abuse, not reasonable pricing, price-regulation or consumer protection at large: Innovative Medicines Canada v. Canada (AG), 2020 FC 725, 174 C.P.R. (4th) 333 at paras. 76-89; Canada (Attorney General) v. Sandoz Canada Inc., 2015 FCA 249, 390 D.L.R. (4th) 691 at para. 26; ICN Pharmac......
Request a trial to view additional results
6 cases
-
Innovative Medicines Canada v. Canada (Attorney General), 2022 FCA 210
...decision to enact section 6 of S.O.R./2019-298—to change the list of comparator countries—was reasonable and, thus, the section was valid: 2020 FC 725 (per Manson J.). [7] For the reasons that follow, I agree with the Federal Court. Therefore, I would dismiss the appeal with costs. B. Analy......
-
TransAlta Generation Partnership v Alberta (Minister of Municipal Affairs),
...The Federal Court decision in Innovative Medicines Canada v Canada (Attorney General), 2020 FC 725 is similarly distinguishable. The court considered the meaning of the words “price” and “sale” in Regulations Amending the Patented Medicines Regulations (Additiona......
-
Alexion Pharmaceuticals Inc. v. Canada (Attorney General),
...patent abuse, not reasonable pricing, price-regulation or consumer protection at large: Innovative Medicines Canada v. Canada (AG), 2020 FC 725, 174 C.P.R. (4th) 333 at paras. 76-89; Canada (Attorney General) v. Sandoz Canada Inc., 2015 FCA 249, 390 D.L.R. (4th) 691 at para. 26; ICN Pharmac......
-
Janssen Inc. v. Canada (Health), 2023 FC 870
...Court continued to be guided by the Katz approach, mindful of this debate [see Innovative Medicines Canada v Canada (Attorney General), 2020 FC 725 at paras 66-72; Bertrand v Acho Dene Koe First Nation, 2021 FC 287 at paras [57] The Federal Court of Appeal weighed into this debate in Portno......
Request a trial to view additional results
18 firm's commentaries
-
Canadian Patent Law 2022: A Year In Review
...prices or setting reasonable prices was rejected by the Federal Court (Innovative Medicines Canada v Canada (Attorney General), 2020 FC 725), a decision upheld by the Federal Court of Appeal, 2022 FCA 210). The constitutionality of the revision of the basket of comparator countries was also......
-
What To Expect In 2021: Pending Patent Decisions From The Federal Courts
...GP, 2019 FC 829. 2. Addressed by in colleagues' article here. 3. Innovative Medicines Canada et al v The Attorney General of Canada, 2020 FC 725. Currently under 4. Merck Canada Inc c Procureur général du Canada, 2020 QCCS 4541. Notice of Appeal filed January 25, 2021. 5. See our colleagues......
-
Federal Court releases decision on validity of the Amending Regulations of the Patented Medicines Regulations
...Innovative Medicines Canada et al. v The Attorney General of Canada et al, 2020 FC 725. This judicial review challenged the validity of the Regulations Amending the Patented Medicines Regulations (Additional Factors and Information Reporting Requirements) (discussed here), which were publis......
-
2021 Year In Review & 2022 Trends To Watch: Pharmaceutical Patents
...This matter relating to amendments to the PMPRB Regulations is currently pending before the FCA. In the underlying decision, reported at 2020 FC 725, Manson J. held that ss. 3(4) of amended PMPRB Regulations, which would expand the price calculation requirement in ss. 4(4) of the PMPRB Regu......
Request a trial to view additional results
2 books & journal articles
-
Table of Cases
...Corporation v Canada (Health), 2008 FC 1409 .......................205, 208 Innovative Medicines Canada v Canada (Attorney General), 2020 FC 725 .....................................................................................296, 299 Innovative Medicines Canada v Canada (Attorney Gen......
-
Patented Medicine Prices Review Board
...41 37 SOR/2019-298, above note 9. 38 Merck QCCA , above note 30 at para 226 [unoicial translation]. 39 SOR/2022-162, above note 10. 40 2020 FC 725 at paras 150–53 [ Innovative Medicines FC]. 41 Innovative Medicines FCA , above note 15 . Patented Medicine Prices Review Board 297 4) PMRs and ......